公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2023 | A deep learning model using chest X-ray for identifying TB and NTM-LD patients: a cross-sectional study | CHIA-JUNG LIU ; Tsai, Cheng Che; LU-CHENG KUO ; Kuo, Po-Chih; MENG-RUI LEE ; JANN-YUAN WANG ; JEN-CHUNG KO ; JIN-YUAN SHIH ; HAO-CHIEN WANG ; CHONG-JEN YU | Insights into imaging | 6 | 4 | |
2017 | Diabetes Mellitus and Latent Tuberculosis Infection: A Systemic Review and Metaanalysis | MENG-RUI LEE ; YA-PING HUANG ; Kuo, Yu-Ting; Luo, Chen-Hao; Shih, Yun-Ju; CHIN-CHUNG SHU ; JANN-YUAN WANG ; JEN-CHANG KO ; CHONG-JEN YU ; HSIEN-HO LIN | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 100 | 88 | |
2005 | Disseminated coccidioidomycosis [8] | Wang C.-Y.; JIH-SHUIN JERNG ; JEN-CHUNG KO ; Lin M.-F.; Hsiao C.-H.; LI-NA LEE ; PO-REN HSUEH ; Kuo S.-H. | Emerging Infectious Diseases | 15 | 12 | |
2015 | Down-regulation of MSH2 expression by Hsp90 inhibition enhances cytotoxicity affected by tamoxifen in human lung cancer cells | JEN-CHANG KO ; Chiu H.-C.; Syu J.-J.; Chen C.-Y.; Jian Y.-T.; Huang Y.-J.; Wo T.-Y.; Jian Y.-J.; Chang P.-Y.; Wang T.-J.; Lin Y.-W. | Biochemical and Biophysical Research Communications | 9 | 9 | |
2021 | Downregulation of p38 MAPK Activation and Radiation-Sensitive 52 Expression Enhances 5-Fluorouracil and Erlotinib-Induced Cytotoxicity in Human Lung Squamous Cells | JEN-CHUNG KO | Pharmacology | 0 | 0 | |
2021 | Downregulation of Xeroderma Pigmentosum Complementation Group C Expression by 17-Allylamino-17-Demethoxygeldanamycin Enhances Bevacizumab-Induced Cytotoxicity in Human Lung Cancer Cells | Chen J.-C.; JEN-CHANG KO ; Taso Y.-C.; Cheng H.-H.; Chen T.-Y.; Yen T.-C.; Lin Y.-W. | Pharmacology | 3 | 3 | |
2004 | Dual and opposing roles of ERK in regulating G1 and S-G 2/M delays in A549 cells caused by hyperoxia | JEN-CHUNG KO ; Wang Y.-T.; Yang J.-L. | Experimental Cell Research | 18 | 14 | |
2020 | Effect of β-Blocker in Treatment-Naïve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs | CHIA-HAO CHANG ; Lee C.-H.; JEN-CHUNG KO ; LIH-YU CHANG ; Lee M.-C.; Zhang J.-F.; JANN-YUAN WANG ; JIN-YUAN SHIH ; CHONG-JEN YU | Frontiers in Oncology | 9 | 8 | |
2021 | Efficacy and safety of cone-beam computed tomography-derived augmented fluoroscopy combined with endobronchial ultrasound in peripheral pulmonary lesions | KAI-LUN YU ; SHUN-MAO YANG ; Ko, Huan-Jang; Tsai, Hui-Yu; JEN-CHUNG KO ; CHING-KAI LIN ; CHAO-CHI HO ; JIN-YUAN SHIH | Respiration | 19 | 18 | |
2010 | Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2 | JEN-CHUNG KO ; Su Y.-J.; Lin S.-T.; Jhan J.-Y.; Ciou S.-C.; Cheng C.-M.; Chiu Y.-F.; Kuo Y.-H.; Tsai M.-S.; Lin Y.-W. | Lung Cancer | 48 | 43 | |
2009 | Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation | Chen R.-S.; Jhan J.-Y.; Su Y.-J.; Lee W.-T.; Cheng C.-M.; Ciou S.-C.; Lin S.-T.; Chuang S.-M.; JEN-CHUNG KO ; Lin Y.-W. | Experimental Cell Research | 28 | 26 | |
2021 | Exploring volatile organic compounds in breath for high-accuracy prediction of lung cancer | PING-HSIEN TSOU ; Lin Z.-L.; Pan Y.-C.; Yang H.-C.; CHIEN-JEN CHANG ; SHENG-KAI LIANG ; Wen Y.-F.; Chang C.-H.; LIH-YU CHANG ; KAI-LUN YU ; CHIA-JUNG LIU ; LI-TA KENG ; MENG-RUI LEE ; JEN-CHUNG KO ; Huang G.-H.; Li Y.-K. | Cancers | 33 | 19 | |
2019 | Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter prospective SMILE study | Wei Y.-F.; Huang W.-T.; Liu T.-C.; Shieh J.-M.; Chian C.-F.; Wu M.-F.; Chang C.-C.; Lin C.-H.; JEN-CHUNG KO ; Lin C.-M.; Hsia T.-C. | Journal of Cancer | 7 | 6 | |
2015 | Factors associated with subsequent nontuberculous mycobacterial lung disease in patients with a single sputum isolate on initial examination | MENG-RUI LEE ; Yang C.-Y.; CHIN-CHUNG SHU ; CHING-KAI LIN ; Wen Y.-F.; Lee S.-W.; JEN-CHUNG KO ; JANN-YUAN WANG ; LI-NA LEE ; CHONG-JEN YU | Clinical Microbiology and Infection | 22 | 18 | |
2021 | Functional Status After Pulmonary Rehabilitation as a Predictor of Weaning Success and Survival in Patients Requiring Prolonged Mechanical Ventilation | LI-TA KENG ; SHENG-KAI LIANG ; Tseng C.-P.; Wen Y.-F.; PING-HSIEN TSOU ; CHIA-HAO CHANG ; LIH-YU CHANG ; KAI-LUN YU ; MENG-RUI LEE ; JEN-CHUNG KO | Frontiers in Medicine | 2 | 1 | |
2017 | Gefitinib or erlotinib in previously treated non–small-cell lung cancer patients: a cohort study in Taiwan | LIH-YU CHANG ; Lee C.-H.; JEN-CHANG KO ; Chang L.-Y.; Lee M.-C.; JANN-YUAN WANG ; CHONG-JEN YU | Cancer Medicine | 8 | 7 | |
2022 | Heat shock protein 90 inhibitor 17-AAG down-regulates thymidine phosphorylase expression and potentiates the cytotoxic effect of tamoxifen and erlotinib in human lung squamous carcinoma cells | JEN-CHUNG KO ; Chen, Jyh-Cheng; Hsieh, Jou-Min; Tseng, Pei-Yu; Chiang, Chen-Shan; Liu, Li-Ling; Chien, Chin-Cheng; Huang, I-Hsiang; Chang, Qiao-Zhen; Mu, Bo-Cheng; Lin, Yun-Wei | Biochemical pharmacology | 3 | 2 | |
2012 | HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells | JEN-CHANG KO ; Chen H.-J.; Huang Y.-C.; Tseng S.-C.; Weng S.-H.; Wo T.-Y.; Huang Y.-J.; Chiu H.-C.; Tsai M.-S.; Chiou R.Y.Y.; Lin Y.-W. | Regulatory Toxicology and Pharmacology | 17 | 18 | |
2023 | Incidence of and Risk Factors for Acute Kidney Injury During Antituberculosis Treatment: A Prospective Cohort Study and Literature Review | CHIA-HAO CHANG ; LIH-YU CHANG ; JEN-CHUNG KO ; Wen, Yueh-Feng; CHIEN-JEN CHANG ; LI-TA KENG ; PING-HSIEN TSOU ; KAI-LUN YU ; JANN-YUAN WANG ; CHONG-JEN YU | Infectious diseases and therapy | 2 | 1 | |
2013 | Inhibition of p38 MAPK-dependent MutS homologue-2 (MSH2) expression by metformin enhances gefitinib-induced cytotoxicity in human squamous lung cancer cells | JEN-CHANG KO ; Chiu H.-C.; Wo T.-Y.; Huang Y.-J.; Tseng S.-C.; Huang Y.-C.; Chen H.-J.; Syu J.-J.; Chen C.-Y.; Jian Y.-T.; Jian Y.-J.; Lin Y.-W. | Lung Cancer | 22 | 20 | |